Development of pharmacological treatments for Alzheimer-type dementia.
作者信息
Cornwall J, Corn T H
机构信息
Medical Division, Glaxo Group Research Limited, Greenford, Middlesex, UK.
出版信息
J R Soc Med. 1994;87 Suppl 23(Suppl 23):19-21.
Abstract
摘要
相似文献
1
Development of pharmacological treatments for Alzheimer-type dementia.阿尔茨海默病型痴呆症药物治疗的进展
J R Soc Med. 1994;87 Suppl 23(Suppl 23):19-21.
2
Update on cholinergic enhancement therapy for Alzheimer disease.阿尔茨海默病胆碱能增强疗法的最新进展。
Bull Clin Neurosci. 1987;52:34-7.
3
[The cholinergic perspectives in the treatment of Alzheimer's disease: tacrine].
Rev Clin Esp. 1995 Jul;195(7):473-8.
4
Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.阿尔茨海默病的治疗：胆碱能方法的评估。
Acta Neurol Belg. 1999 Jun;99(2):96-106.
5
Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's dementia.与他克林治疗阿尔茨海默病性痴呆相关的胆碱能谵妄和神经毒性。
Psychosomatics. 1996 May-Jun;37(3):299-301. doi: 10.1016/S0033-3182(96)71569-4.
6
Tacrine for Alzheimer's disease.
JAMA. 1994 Dec 28;272(24):1896; author reply 1897. doi: 10.1001/jama.272.24.1896d.
7
Alzheimer's disease: the role of tacrine therapy.阿尔茨海默病：他克林疗法的作用
Iowa Med. 1995 Oct;85(10):409-11.
8
Effect of tacrine in Alzheimer's disease: or non-effect?
Med J Aust. 1994 Sep 19;161(6):348-9.
9
Assessment issues in clinical trials of tetrahydroaminoacridine and studies to alter decline in Alzheimer disease.四氢氨基吖啶临床试验中的评估问题以及改变阿尔茨海默病病情恶化的研究
Alzheimer Dis Assoc Disord. 1991;5 Suppl 1:S37-9.
10
Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
JAMA. 1998 Nov 25;280(20):1777-82. doi: 10.1001/jama.280.20.1777.
本文引用的文献
1
A population-based study of dementia in 85-year-olds.一项针对85岁老人痴呆症的基于人群的研究。
N Engl J Med. 1993 Jan 21;328(3):153-8. doi: 10.1056/NEJM199301213280301.
2
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.阿尔茨海默病的临床诊断：美国国立神经疾病与中风研究所-阿尔茨海默病及相关疾病协会工作组在卫生与公众服务部阿尔茨海默病特别工作组主持下的报告。
Neurology. 1984 Jul;34(7):939-44. doi: 10.1212/wnl.34.7.939.
3
The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.老年受试者痴呆症的定量测量与大脑灰质老年变化之间的关联。
Br J Psychiatry. 1968 Jul;114(512):797-811. doi: 10.1192/bjp.114.512.797.
4
Human memory and the cholinergic system. A relationship to aging?人类记忆与胆碱能系统。与衰老有关系吗？
Arch Neurol. 1974 Feb;30(2):113-21. doi: 10.1001/archneur.1974.00490320001001.
5
Brain-decarboxylase activities as indices of pathological change in senile dementia.
Lancet. 1974 Jun 22;1(7869):1247-9. doi: 10.1016/s0140-6736(74)90003-8.
6
Piracetam combined with lecithin in the treatment of Alzheimer's disease.吡拉西坦联合卵磷脂治疗阿尔茨海默病。
Neurobiol Aging. 1986 Jul-Aug;7(4):269-76. doi: 10.1016/0197-4580(86)90007-2.
7
Cognition activators.认知激活剂。
Med Res Rev. 1988 Jul-Sep;8(3):353-91. doi: 10.1002/med.2610080303.
8
Tacrine in the treatment of Alzheimer's disease. A clinical update and recent pharmacologic studies.他克林治疗阿尔茨海默病：临床进展与近期药理学研究
Eur Neurol. 1989;29 Suppl 3:28-32. doi: 10.1159/000116478.
9
Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.唐氏综合征和阿尔茨海默病中的淀粉样蛋白A4及其前体
N Engl J Med. 1989 Jun 1;320(22):1446-52. doi: 10.1056/NEJM198906013202203.
10
Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease.与阿尔茨海默病相关的淀粉样前体蛋白片段的神经毒性
Science. 1989 Jul 28;245(4916):417-20. doi: 10.1126/science.2474201.
Zotero 插件